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ABSTRACT 
The purpose of this research was to develop oral dispersible tablets of montelukast sodium. Montelukast sodium is most commonly used in treatment of 
Asthma. Oral dispersible tablets were prepared by using a direct compression method employing superdisintegrants such as low substituted  hydroxyl propyl 
cellulose, crospovidone, croscarmellose sodium, and sodium starch glycolate. Tablets were evaluated for weight variation, thickness, hardness, friability, drug 
content, in vitro disintegration time, and drug release. Other parameters such as wetting time and drug-excipient compatibility were also evaluated.  The 
tablets' hardness was maintained in the range of 3-4 kg and friability was <1% for all formulations. All tablet formulations disintegrated rapidly in vitro within 
10 to 30sec. Release of drug was faster from formulations containing 7.5% crospovidone (MF11) compared to the marketed  tablets.  Kinetic studies indicated 
that all the formulations followed first order release with diffusion mechanism. Finally, it can be reasonably expected that the obtained drug dissolution rate 
improvement will result in an increase of its bioavailability, with the possibility of reducing drug dosage and side effects. 
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INTRODUCTION 
Fast  disintegrating  solid  dosage  forms  have  received  ever-
increasing demand during the last decade, and the field has 
become a rapidly growing area in the pharmaceutical industry 
because of the advantages of easy administration to patients 
who have difficulty swallowing, more rapid drug absorption, 
patient convenience, and improved patient compliance
1,2. The 
popularity and usefulness of the formulation resulted in the 
development  of  several  related  technologies  and  processes 
such as freeze drying, tablet moulding, direct compression, 
spray drying, rotary process
 and sublimation method
3,4. 
Direct  compression  represents  a  simple  and  cost  effective 
tablet  manufacturing  technique.  Use  of  conventional 
equipment,  commonly  available  excipients  and  limited 
number  of  processing  steps  are  the  advantages  of  this 
technique.  Directly  compressed  tablet's  disintegration  and 
solubilization  depends  on  single  or  combined  action  of 
disintegrants,  water  soluble  excipients  and  effervescent 
agents
5.  The  commonly  used  superdisintegrants  are 
croscarmellose  sodium,  crospovidone    and  sodium  starch 
glycolate.  In many orally disintegrating tablet technologies 
based  on  direct  compression,  the  addition  of 
superdisintegrants  principally  affects  the  rate  of 
disintegration and hence the dissolution. 
The key properties of fast disintegrating tablets (FDTs) are 
fast  absorption  or  wetting  of  water  into  the  tablets  and 
disintegration  of  associated  particles  into  individual 
components for fast dissolution. This requires not only that 
excipients  should  have  high  wettability,  but  also  that  the 
tablet structure should have a highly porous network 
3. 
Montelukast  sodium
6  is  a  leukotriene  receptor  antagonist 
(LTRA)  used  in  maintenance  treatment  of  asthma  and  to 
relieve symptoms of seasonal allergies  and its bioavailability 
is 63%
7. It is usually administered orally. 
 It has extensive 
first-pass metabolism and show a very poor dissolution rates 
in  order  to  overcome  this  problem  preparation  of  oral 
dispersable tablets. 
The main goal  of the present investigation was to develop 
mountelkast    oral  dispersible  tablets  consisting  of  sodium 
starch glycolate, crospovidone, croscarmellose sodium and L- 
hydroxy  propyl  cellulose  by  using  direct  compression 
technique. 
MATERIALS AND METHODS 
Montelukast  sodium  was  received  as  a  gift  sample  from 
Hetero Drugs, Hyderabad India. Sodium starch glycolate, L- 
hydroxyl  propyl  cellulose  croscarmellose  sodium  and 
crospovidone  was  obtained  as  gift  sample  from  Signet 
Chemicals  Mumbai.  All  other  materials  like,  mannitol, 
microcrystalline cellulose, magnesium stearate, talc used was 
of analytical grade and procured from commercial sources. 
Compatibility Studies 
The compatibility of drug in the formulation was confirmed 
by IR spectra of pure drug and formulations were determined 
between 4500-450cm
-1 using Shimadzu 160a, Kyoto, Japan 
by KBr Disc method. 
Formulation  of  Oral  Disintegrating  Tablets  of 
Montelukast sodium  
Montelukast  sodium  tablets  were  prepared  by  direct 
compression method according formula given in table I. The 
drug along with the excipients was taken and observed for 
any  aggregates  or  lumps  which  were  then  triturated  and 
passed through sieve number 40. Then finally lubricants and 
glidants are passed through the same sieve in to the powder 
mass. This powder mass was then loaded in to a blender for 
obtaining a uniform powder blend. The mixture blends of all 
the  formulation  were  subjected  for  pre-compression 
parameter
8 like bulk density, tapped density, angle of repose, 
compressibility  index  and  hausner  ratio.  The  tablets  were 
compressed using  6.2 mm flat punch to get a tablets of 100 
mg  weight  using    MT  Rimek  12  station  compression 
machine. 
Evaluation of tablets 
Weight Variation  
Twenty tablets were selected at a random and average weight 
was  determined. Then  individual  tablets  were  weighed  and 
the individual weight was compared with an average weight. 
None of the tablets deviated from the average weight by more 
than ±5% 
9.  
% Weight variation = [(Average weight - Individual weight) / 
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Friability  
The  friability  of  ten  tablets  was  determined  using  Roche 
friabilator at 25 rpm for 4 minutes. The tests were carried out 
in triplicate. The friability was expressed in terms of weight 
loss and was calculated as the percentage (% ± SD) of the 
initial weight according to the following equation: 
 f =W0 - W t / W0 × 100% 
where  f = friability, W0= initial weight of tablets before the 
tests, and Wt = tablets weight after the tests. 
% Friability of Tablets less than 1% are considered 
acceptable
10. 
Thickness  
The thickness were measured by using vernier calliper and 
values  were  tabulated.  Three  tablets  of  each  batch  were 
measured. 
Hardness  
Hardness  indicates  the  ability  of  a  tablet  to  withstand 
mechanical shock while handling. The hardness of the tablets 
was  determined  using  Monsanto  hardness  tester.  It  is 
expressed in kg/cm2. Three tablets were randomly picked and 
hardness  of  the  same  tablets  from  each  formulation  was 
determined. The  mean  and  standard  deviation  values  were 
also calculated
11. 
Drug Content  
Twenty  tablets  of  each  formulation  were  weighed  and 
powdered. The  quantity  of  powder  equivalent to  10  mg  of 
Montelukast sodium was transferred into a 100 ml standard 
flask and volume made up with 0.5% Sodium lauryl sulphate 
and absorbance of the resulting solution was observed at 240 
nm.   
In-vitro Disintegration time 
The  disintegration  time  was  measured  using  disintegration 
test apparatus. Place one tablet in each of the 6 tubes of the 
basket and run the apparatus using pH 6.8 (simulated saliva 
fluid) maintained at 37°±1°C as the  immersion liquid. The 
assembly should be raised and lowered between 100 cycles 
per  minute.  The  time  in  seconds  taken  for  complete 
disintegration of the tablet with no palpable mass remaining 
in the apparatus was measured and recorded. 
Wetting Time   
Wetting time is closely related to the inner structure of the 
tablets and to the hydrophilicity of the excipient. It is obvious 
that pores size becomes smaller and wetting time increases 
with  an  increase  in  compression  force  or  a  decrease  in 
porosity. The wetting time was measured by a modification of 
the described procedure by Rawas-Qalaji et al
12. The tablet 
was  placed  at  the  center  of  two  layers  of  absorbent  paper 
fitted into a rounded plastic dish with a diameter of 12 cm. 
After the paper was thoroughly wetted with distilled water, 
excess  water  was  completely  drained  out  of  the  dish.  The 
time  required  for  the  water  to  diffuse  from  the  wetted 
absorbent  paper  throughout  the  entire  tablet  was  then 
recorded. 
Water Absorption Ratio  
A piece of tissue paper folded twice was placed in a small 
petri dish containing 6 mL of water. A tablet was put on the 
paper  and  the  time  required  for  complete  wetting  was 
measured.  The  wetted  tablet  was  then  weighed.  Water 
absorption  ratio  R,  was  determined  using  following 
equation
13 
R= Wa - Wb / Wb × 100 
Where, Wa=  weight  of  tablet  after  absorption, Wb=  Initial 
weight of the tablet. 
Invitro Dissolution Studies   
The  dissolution  rate  of  montelukast  sodium  from  the  oral 
dispersable tablet was studied in 900ml of  water  containing   
0.5% sodium laurlyl sulphate  using   Electrolab TDT-08L 
USP dissolution test apparatus with  paddle stirrer at 50 rpm.  
A temperature of 37
oC + 0.5
oC was maintained throughout 
the  study.    One  tablet  containing  10  mg  of  montelukast 
sodium was used in each test.  Samples of dissolution media  
(5 ml) were withdrawn  at  time interval 2, 5, 10, 20, 30, 40, 
50  and  60  min,  and  assayed  for  montelukast  sodium  at 
240nm.  The sample of dissolution fluid withdrawn at each 
time  was  replaced  with  fresh  dissolution  fluid.    The 
dissolution experiments were conducted in triplicate.   
Similarity factor  
Several methods are available for the comparative analysis of 
dissolution  profile.  A  simple  model  independent  approach 
uses  a  difference  factor  (f1)  and  a  similarity  factor  (f2)  to 
compare  dissolution  profiles
14.  The  difference  factor  (f1) 
calculates the percent difference between the two curves at 
each time point and is a measure of the relative error between 
the two curves: 
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The specific procedure to determine difference and similarity 
factors is as follows (FDA). The dissolution profiles of the 
two products, the test product and reference products should 
be determined. Using the mean dissolution values from both 
curves at each time interval, calculate the difference factor 
(f1) and the similarity factor (f2) using above two equations. 
For curves to be considered similar, f1 values should be close 
to 0, and f2 values should be close to 100. Generally, f1values 
up to 15 (0-15) and f2values greater than 50 (50-100) ensure 
sameness or equivalence of the two curves and thus, of the 
performance of the test and reference products. This model 
independent method is most suitable for dissolution profile 
comparison  when  three  to  four  or  more  dissolution  time 
points  are  available. As  further  suggestions  for  the general 
approach,  the  following  recommendations  should  also  be 
considered: The dissolution measurements of the selected and  
market formulation  should be made under exactly the same 
conditions and same time interval like 2, 5 and 10 min.  
Stability studies 
The  optimized  formulation  (MF11)  was  wrapped  in 
aluminum foils and kept in petri dish at 40±2
0C/75±2% RH 
and analyzed for disintegration time,  wetting time and in-
vitro dissolutions study for a period of three months.
  
RESULTS AND DISCUSSION 
In  the  present  study  montelukast  sodium  oral  dispersible 
tablets  were  prepared  by  using  croscarmellose  sodium, 
crospovidone, l- hydroxypropyl cellulose and sodium starch 
glycolate  as  a  disintegrants.  FT-IR  studies  of  montelukast 
sodium  absorption  bands  at  3420  cm
-1  sodium  starch 
glycolate containing tablet formulations, absorption bands at 
3380  cm
-1  L-hydroxy  propyl  cellulose  having  tablet Kanagala Vijaya Sri et al. IRJP 2012, 3 (7) 
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formulations,  absorption  bands  at  3400  cm
-1  and  cross 
povidone  containing tablet formulations, absorption bands at 
3370 cm
-1  indicates OH group. Hence there was no chemical 
and  physical  interactions  between  drug  and  excipients 
showed  in  Figure.1.  The  values  of  pre-compression 
parameters  evaluated  were  within  prescribed  limit  and 
indicated  good  free  flowing  property  as  showed  in table.2. 
Bulk density was found in the range 0.28 to 0.35 g/sqcm and 
tapped  density  in the range  of  0.34 to  0.40 g/sqcm.  Using 
these two density factors hausner`s ratio and compressibility 
index were calculated. The powder blend of all formulations 
had hausner`s ratio less than 1.21 which indicates better flow 
property and compressibility index between 18.18 to 20.16  
which indicates good flowability property. The  flowability 
property of the powder blend was also evidenced with angle 
of  repose  between  28.4
0  to  33.3
0  which  is  below  40
0 
indicating  good  flow  ability.  Hardness,  friability,  weight 
variation,  in-vitro  wetting  time  and  in-vitro  disintegration 
time are shown in table 3. The hardness was found to be in 
the range of 3.4 to 5kg/cm
2 for all the formulations indicating 
good  mechanical  strength  with  an  ability  to  withstand 
physical and mechanical stress conditions while handling. In 
all the formulations the friability values are less than 1% and 
meet the IP limits. All the tablets passed weight variation test 
as  the  percentage  weight  variation  was  within  the 
pharmacopoeial limits. The percentages drug contents of all 
the tablets were found to be between 93.1 to 99.3 of which 
was  within  the  acceptable  limits.  The  results  of  in-vitro 
wetting time and in-vitro disintegration time of all the tablets 
were found to be within the prescribe limits and satisfy the 
criteria of oral dispersible tablets. The in-vitro wetting time 
was found to be in the range of 13 to 40 seconds while the in-
vitro disintegration time was founds in the range of 8 to 40 
seconds  respectively.  It  was  observed  that  when 
croscarmellose  sodium  is  used  as  disintegrant,  the  tablets 
disintegrates  rapidly  within  less  time  due  to  easy  swelling 
ability  of  croscarmellose  sodium  when  compared  to  other 
tablets  prepared  by  using  crospovidone  and  sodium  starch 
glycolate.  Among  the  formulation  of  tablets  the  batch 
containing croscarmellose sodium 7.5% was found to be the 
best  as  compare  to  other  formulations  as  this  formulation 
showed  good  hardness,  good  friability  and    wetting  time 
(21sec) and disintegration time of (12.5sec), which is an ideal 
characteristic of an dispersible type tablet . The cumulative 
percentage of the drug released for formulation MF-11 found 
by  the  dissolution  studies  shows  the  better  drug release  of 
98% within 10 min indicates good bioavailability of the drug 
from these formulations. The dissolution data of montelukast 
sodium  tablets  are  given  in  Table  4  and  Figure  2. 
Croscarmellose  sodium  7.5%  when  comes  in  contact  with 
water gets inflated immediately burst out there by releasing 
the drug in the short duration of time. Similarity factor ‘f2' 
(85.3)  and  dissimilarity  factor  ‘f1'(2.1)  between  dissolution 
profiles of the rapidly disintegrating tablet formulation MF11 
and  the  marketed  formulation  indicated  that  the  two 
dissolution  profiles  were  similar.  The  selected  formulation 
showed  no  significant  variations  for  the  in‐vitro 
disintegration  time,  wetting  time  and  invitro  drug  release 
pattern above mentioned parameters and it was stable for the 
specified time period.  
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Table-1 FORMUALTION COMPOSITION OF MONTELUKAST SODIUM ORAL DISPERSIBLE TABLETS 
Ingredients(mg)  MF1  MF2  MF3  MF4  MF5  MF6  MF7  MF8  MF9  MF10  MF11  MF12 
Montelukast sodium  10  10  10  10  10  10  10  10  10  10  10  10 
Sodium starch glycolate  5  7.5  12.5  -  -  -  -  -  -  -  -  - 
L-hydroxy propyl cellulose  -  -  -  5  7.5  12.5  -  -  -  -  -  - 
Cross povidone  -  -  -  -  -  -  5  7.5  12.5  -  -  - 
Crosscarmellose sodium  -  -  -  -  -  -  -  -  -  5  7.5  12.5 
Orange flavour  1  1  1  1  1  1  1  1  1  1  1  1 
Talc  2  2  2  2  2  2  2  2  2  2  2  2 
Magnesium stearate  2  2  2  2  2  2  2  2  2  2  2  2 
Micro crystalline cellulose  79.5  77  72  79.5  77  72  79.5  77  72  79.5  77  72 
Total weight (mg)  100  100  100  100  100  100  100  100  100  100  100  100 
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Table-2 PRE-COMPRESSION PARAMETERS OF MONTELUKAST SODIUM (Mean±SD n=3) 
Formulations  Bulk density  Tapped density  Carr"s index  Angle of repose
0  Hausneers ratio 
MF-1  7.6±0.1  6.3±0.1  19.3±0.82  28.4±.005  1.19±.008 
MF-2  8.0±0.1  6.7±0.2  18.8±0.79  28.4±.005  1.18±.007 
MF-3  7.7±0.2  6.5±0.3  18.8±.979  32.4±.004  1.18±.009 
MF-4  7.6±0.1  6.4±0.1  18.7±1.71  30.0±.005  1.18±.017 
MF-5  8.7±0.3  7.2±0.2  21.3±1.85  31.7±.006  1.21±.018 
MF-6  7.6±0.1  6.2±0.3  21.2±0.83  33.3±.004  1.21±.008 
MF-7  8.1±0.7  6.7±0.4  20.3±1.02  29.1±.009  1.20±.010 
MF-8  8.7±0.1  7.2±0.2  19.7±1.67  29.7±.005  1.19±.016 
MF-9  8.0±0.4  6.7±0.1  19.3±0.16  31.8±.005  1.19±.006 
MF-10  7.4±0.3  6.2±0.1  20.4±2.78  32.4±.004  1.20±.027 
MF-11  7.0±0.2  5.9±0.1  19.1±2.12  29.7±.006  1.19±.021 
MF-12  7.4±0.1  6.1±0.1  21.3±3.17  32.3±.004  1.21±.031 
 
Table-3 EVALUATION OF MONTELUKAST SODIUM ORAL DISPERSIBLE TABLETS  CONTAINING  SUPERDISINTEGRANTS 
( Mean±SD n=3) 
Formulations  Weight 
variation 
(mg) 
Thickness in 
(mm) 
Hardness 
 
Friability 
% w/w 
Drug 
content 
Wetting 
time (sec) 
Water absorption 
ratio 
Disintegration 
Time(sec) 
 
MF1  99.1±1.0  2.8±0.1  3.7±0.2  0.35±.005  88.1±0.1  40.2±5.5  153.8±1.2 
 
40.1±0.4 
 
MF2  99.3±1.5  3.1±0.2  3.9±0.1  0.92±.004  97.0±0.1  38.3±3.0  171.1±1.5 
 
22.3±1.2 
MF3  97.3±2.1  3.2±0.2  3.8±0.1  0.63±.005  94.1±0.1  32.8±2.5  140.5±2.0  25.2±1.5 
MF4  101.1±1.5  3.1±0.1  3.4±0.3  0.60±.005  99.2±0.1  33.4±2.0  201.1±1.5  28.2±1.5 
MF5  98.4±1.2  3.0±0.1  3.8±0.1  0.33±.002  97.1±0.1  32.5±2.5  163.3±1.0  23.7±2.0 
MF6  100.1±1.0  3.1±0.2  3.5±0.2  0.96±.006  91.3±.0.2  29.6±1.8  197.1±1.1  17.5±1.8 
MF7  98.7±2.5  3.1±0.1  3.8±0.1  0.64±.004  93.2±0.1  36.7±1.2  155.7±0.9  27.1±2.5 
MF8  100.1±3.2  3.0±0.1  3.6±0.2  0.31±.005  94.3±0.1  29.4±2.0  163.6±1.3  19.1±1.8 
MF9  99.8±2.0  3.0±0.1  3.8±0.1  0.65±.004  85.6±0.2  23.5±1.2  184.8±0.8  18.8±1.5 
MF10  99.3±1.5  2.8±0.3  3.8±0.1  0.34±.003  86.3±0.1  38.4±3.0  147.1±1.7  15.7±1.8 
MF11  99.9±1.0  3.0±0.1  3.3±0.3  0.63±.003  98.3±0.1  21.4±2.1  200.2±1.6  12.5±2.2 
MF12  97.4±2.5  2.9±0.1  3.8±0.1  0.63±.004  94.6±0.1  26.5±2.1  198.2±1.0  20.5±3.0 
 
Table-4 DISSOLUTION PARAMETERS  OF MONTELUKAST SODIUM ORAL DISPERSIBLE TABLETS 
Formulations  k
-1  t ½  r  DP 10 
MF1  0.09  7.5  0.929  66.7±5.0 
MF2  0.05  11.5  0.977  83.1±2.1 
MF3  0.09  7.0  0.959  88.5±6.0 
MF4  0.09  7.2  0.974  86.3±1.1 
MF5  0.11  5.8  0.962  87.7±1.3 
MF6  0.07  8.8  0.852  86.7±3.3 
MF7  0.07  9.7  0.967  67.5±0.9 
MF8  0.10  6.8  0.925  76.3±2.4 
MF9  0.06  10.0  0.778  82.7±1.2 
MF10  0.04  14.3  0.724  85.9±2.8 
MF11  0.12  5.6  0.822  98.0±1.4 
MF12  0.07  9.7  0.793  89.5±2.2 
Marketed formulation  0.11  6.0  0.822  95.9±1.4 
 
 
 
 
Figure-1 FT-IR Spectra  of  montelukast and its oral dispersible tablets 
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Figure-2 Dissolution profiles of  montelukast  oral dispersible tablets 
 